Application Study Of Circulating Tumor Cells In Non-small Cell Lung Cancer Diagnosis And Treatment

PurposeTo analyze the relationship between CTCs and the clinicopathological features of NSCLC;to observe the correlation between CTCs and Tumor Markers(TMs)expression in NSCLC.;to investigate the relationship between CTCs and EGFR mutation status.MethodsThe clinical and pathological data of 94 patients with NSCLC were reviewed.CTCs were identified and enumerated by immunomagnetic negative enrichment coupled with fluorescence in situ hybridization(FISH).TMs were detected by electrochemiluminescence assays in 62 patients prior to pathological diagnosis of NSCLC.Driver oncogene status were analyzed in 71 patients using the amplification and mutation system(ARMS).Results?.Compared with patients in early stage,the number of CTCs can be extraordinarily large in advanced NSCLC patients during the course of diagnosis and management.?.The positive rate of baseline cyfra21-1 and SCC is different from that of baseline CTCs(p=0.0233,0.0412).?.There is no significant difference in the trend of CTCs change during the course of diagnosis and treatment between the TMs positive group and the negative group(p>0.05).?.EGFR mutated group and the wild type group are different in terms of gender,smoking status and histological type(p-0.0033,0.0343,0.0308).Yet there is no significant difference between the two groups above in terms of the CTCs change trend,the organs involved in distant metastasis and other clinicopathological features of NSCLC(p>0.05).ConclusionPatients with advanced NSCLC are more likely to have more CTCs.CTCs test results of NSCLC patients are not consistent with TMs test results.Baseline TMs cannot be used to predict CTCs change trend during the course of diagnosis and treatment.The CTCs change trend and distant metastasis site are independent of the EGFR mutation state.